Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Rigel raises 2026 guidance as VEPPANU launches; strong Q2 results

Aug 4, 2026, 4:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q2 results underpin earnings quality; VEPPANU licensing adds a high-value, near-term growth driver and potential new revenue streams; raised 2026 guidance signals improved visibility. Cash burn from upfront could weigh modestly, but the composite impact is positive for valuation and sentiment, especially with a mid-August launch catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Rigel reported a solid Q2 with $78.7 million in total revenues and $17.3 million in net income, driven by strong TAVALISSE performance. The company secured VEPPANU via exclusive global licensing from Arvinas and Pfizer, with US availability expected mid-August, signaling a meaningful expansion of its oncology portfolio. R289 progress remains on plan, and guidance for 2026 was raised to $285–$295 million.

Q2 2026 revenues $78.7M; net income $17.3M.
VEPPANU in-license secured; upfront $70.0M; US launch expected mid-August 2026.
2026 outlook raised to $285–$295M; VEPPANU excluded from guidance.
R289 Phase 1b in lower-risk MDS on track; data by year-end.
Alison L. Hannah appointed Chief Medical Officer; conference call at 4:30 p.m. ET.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Rigel raises 2026 guidance as VEPPANU launches; strong Q2 results

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential